Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: Effect on wild-type and mutant HBV

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 2049-2054

  Semaine, Wassila ^a   Johar, Monika ^a   Tyrrell, D Lorne J ^a   Kumar, Rakesh ^a   Agrawal, B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 5 BROMOURACIL; 1,3 DIOXOLANE; ANTIVIRUS AGENT; CHLORINE DERIVATIVE; CHLOROTRIMETHYLSILANE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; POTASSIUM IODIDE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CHRONIC HEPATITIS; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS; VERO CELL; VIRUS CULTURE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; DUCKS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; PYRIMIDINE NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 33645411189     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058271d     Document Type: Article

References (43)

1. Malik, A. H.; Lee, W. M. Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium. Ann. Intern. Med. 2000, 132, 723-731.
2. Lok, A. S. Hepatitis B Infection: Pathogenesis and Management. J. Hepatol. 2000, 32 (Suppl. 1), 89-97.
3. Kane, M. A. The Global Epidemiology of Hepatitis B. Soz. Praventivmed. 1998, 43 (Suppl. 1), S24-S26.
4. Medical Microbiology; Mims, C. A., Ed.; Mosby: London, 1993; Chapter 38.
5. Perrillo, R. P.; Schiff, E. R.; Davis, G. L.; Bodenheimer, H. C.; Lindsay, K.; Payne, J.; Dienstag, J. L.; O'Brien, C.; Tamburro, C.; Jacobson, I. M. A Randomized Controlled Trial of Interferon Alfa-2b Alone and After Prednisone Withdrawal for the Treatment of Chronic Hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990, 323, 295-301.
6. Wong, D. K. H.; Cheung, A. M.; O'Rourke, K.; Naylor, C. D.; Detsky, A. S.; Heathcote, J. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. A Meta-Analysis. Ann. Intern. Med. 1993, 119, 312-323.
7. Nevens, F.; Main, J.; Honkoop, P.; Tyrrell, D. L.; Barber, J.; Sullivan, M. T.; Fevery, J.; DeMan, R. A.; Thomas, H. C. Lamivudine Therapy for Chronic Hepatitis B: A Six Month Randomized Dose-ranging Study. Gastroenterology 1997, 113, 1258-1263.
8. Liaw, Y. F.; Leung, N. W.; Chang, T. T.; Guan, R.; Tai, D. I.; Ng, K. Y.; Chien, R. N.; Dent, J.; Roman, L.; Edmundson, S.; Lai, C. L. Effects of Extended Lamivudine Therapy in Asian Patients with Chronic Hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000, 119, 172-180.
9. Gilson, R. J. C.; Chopra, K.; Murray, L. I. Placebo-controlled Phase I/II study of Adefovir Dipivoxil in Patients with Chronic Hepatitis B Infection. Hepatology 1996, 24 (Suppl. 1), 281A.
10. Hepsera Full Prescribing Information. Gilead Sciences. 09/2002, pp 1-18.
11. Torresi, J.; Locarnini, S. Antiviral Chemotherapy for the Treatment of Hepatitis B Virus Infections. Gastroenterology 2000, 118 (Suppl. 2), 83-103.
12. Delaney, W. E., IV.; Edwards, R.; Colledge, D.; Shaw, T.; Torresi, J.; Miller, T. G.; Isom, H. C.; Bock, C. T.; Manns, M. P.; Trautwein, C.; Locarnini, S. Cross-resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 2001, 45, 1705-1713.
13. Zoulim, F. Detection of Hepatitis B Virus Resistance to Antivirals. J. Clin. Virol. 2001, 21, 243-253.
14. Leung, N. Treatment of Chronic Hepatitis B: Case Selection and Duration of Therapy. J. Gastroenterol. Hepatol. 2002, 17, 409-414.
15. Colledge, D.; Locarnini, S.; Shaw, T. Synergistic Inhibition of Hepadnaviral Replication by Lamivudine in Combination with Penciclovir in vitro. Hepatology 1997, 26, 216-225.
16. Leung, N. Clinical Experience with Lamivudine. Semin. Liver Dis. 2002, 22 (Suppl. 1), 15-22.
17. Tipples, G. A.; Ma, M. M.; Fischer, K. P.; Bain, V. G.; Kneteman, N. M.; Tyrrell, D. L. Mutation in HBV RNA-dependent DNA Polymerase Confers Resistance to Lamivudine in vivo. Hepatology 1996, 24, 714-717.
18. Bartholomew, M. M.; Jansen, R. W.; Jeffers, L. J.; Reddy, K. R.; Johnson, L. C.; Bunzendahl, H.; Condreay, L. D.; Tzakis, A. G.; Schiff, E. R.; Brown, N. A. Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection after Orthotopic Lver Transplantation. Lancet 1997, 349, 20-22.
19. Liaw, Y.-F. Therapy of Chronic Hepatitis B: Current Challenges and Opportunities. J. Viral Hepatol. 2002, 9, 393-399.
20. Ling, R.; Mutimer, D.; Ahmed, M.; Boxall, E H.; Elias, E.; Dusheiko, G. M.; Harrison, T. J. Selection of Mutations in the Hepatitis B Virus Polymerase During Therapy of Transplant Recipients with Lamivudine. Hepatology 1996, 24, 711-713.
21. Chan, T. M.; Fang, G. X.; Tang, C. S. O.; Cheng, I. K. P.; Lai, K. N.; Ho, S. K. N. Preemptive Lamivudine Therapy Based on HBV DNA Level in HBsAg-positive Kidney Allograft Recipients. Hepatology 2002, 36, 1246-1252.
22. Lai, C. L. Genotypic Resistance to Lamivudine in a Prospective, Placebo Controlled Multicenter Study in Asia of Lamivudine Therapy for Chronic Hepatitis B Virus Infection: Incidence, Kinetics of Emergence and Correlation with Disease Parameters. Hepatology 1997, 26, 259A.
23. Dienstag, J. L.; Schiff, E. R.; Wright, T. L.; Perrillo, R. P.; Hann, H.-W. L.; Goodman, Z.; Crowther, L. B. S.; Condreay, L. D.; Woessner, M. B. S.; Rubin, M.; Brown, N. A.; Brown, N. A. The U. S. Lamivudine Investigator Group. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. N. Engl. J. Med. 1999, 341, 1256-1263.
24. Lai, C. L.; Chien, R. N.; Leung, N. W.; Chang, T. T.; Guan, R.; Tai, D. L; Ng, K. Y.; Wu, P. C.; Dent, J. C.; Barber, J.; Stephenson, S. L.; Gray, D. F. A One-year Trial of Lamivudine for Chronic Hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998, 339, 64-70.
25. Leung, N. W. Y.; Lai, C. L.; Chang, T. T.; Guan, R.; Lee, C. M.; Ng, K. Y.; Lim, S. G.; Wu, P. C.; Dent, J. C.; Edmundson, S.; Condreay, L. D.; Chien R. N. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended Lamivudine Treatment in Patients with Chronic Hepatitis B Enhances Hepatitis B e Antigen Seroconversion Rates: Results After 3 Years of Therapy. Hepatology 2001, 33, 1527-1532.
26. Allen, M. I.; Deslauriers, M.; Andrews, C. W.; Tipples, G. A.; Walters, K. A.; Tyrrell, D. L.; Brown, N.; Condreay, L. D.; Lamivudine Clinical Investigation Group. Hepatology 1998, 27, 1670-1677.
27. Fischer, K. P.; Tyrrell, D. L. Generation of Duck Hepatitis B Virus Polymerase Mutants through Site-directed Mutagenesis which Demonstrate Resistance to Lamivudine [(-)-Beta-L-2′, 3′-dideoxy-3′- thiacytidine] in vitro. Antimicrob. Agents Chemother. 1996, 40, 1957-1960.
28. Melegari, M.; Scaglioni, P. P.; Wands, J. R. Hepatitis B Virus Mutants Associated with 3TC and Famciclovir Administration are Replication Defective. Hepatology 1998, 27, 628-633.
29. Das, K.; Xiong, X.; Yang, H.; Westland, C. E.; Gibbs, C. S.; Sarafianos, S. G.; Arnold, E. Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC). J Virol. 2001, 75, 4771-4779.
30. Seignères, B.; Pichoud, C.; Germon, S.; Furman, P.; Trépo, C.; Zoulim, F. Inhibitory Activity of New Nucleoside Analogues on Wild-type and YMDD Mutants of the Hepadnavirus Reverse Transcriptase. Antiviral Res. 2000, 46, A56.
31. Kelley, J. L.; Kelsey, J. E.; Hall, W. R.; Krochmal, M. P.; Schaeffer, H. J. Pyrimidine Acyclic Nucleosides. 1-[(2-Hydroxyethoxy)methyl]-pyrimidines as Candidate Antivirals. J. Med. Chem. 1981, 24, 753-756.
32. Kumar, R.; Sharma, N.; Nath, M.; Saffran, H. A.; Tyrrell, D. J. Synthesis and Antiviral Activity of Novel Acyclic Nucleoside Analogues of 5-(1-Azido-2-haloethyl)uracils, J. Med. Chem. 2001, 44, 4225-4229.
33. Kumar, R.; Tyrrell, D. J. Novel 5-Vinyl Pyrimidine Nucleosides with Potent anti-Hepatitis B Virus Activity. Bioorg. Med. Chem. Lett. 2001, 11, 2917-2920.
34. Kumar, R.; Nath, M.; Tyrrell, D. J. Design and Synthesis of Novel 5-Substituted Acyclic Pyrimidine Nucleosides as Potent and Selective Inhibitors of Hepatitis B Virus. J Med. Chem. 2002, 45, 2032-2040.
35. Robins, M. J.; Hatfield, P. W.; Balzarini, J.; De Clercq, E. Nucleic Acid Related Compounds. 47. Synthesis and Biological Activities of Pyrimidine and Purine "Acyclic" Nucleoside Analogs. J. Med. Chem. 1984, 27, 1486-1492.
36. Rosowsky, A.; Kim, S.-H.; Wick, M. Synthesis and Antitumor Activity of an Acyclonucleoside Derivative of 5-Fluorouracil. J. Med. Chem. 1981, 24, 1177-1181.
37. Walters, K. A.; Tipples, G. A.; Allen, M. I.; Condreay, L. D.; Addison, W. R.; Tyrrell, L. Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. Antimicrob. Agents Chemother. 2003, 47, 1936-1942.
38. Ono, S. K.; Kato, N.; Shiratori, Y.; Kato, J.; Goto, T.; Schinazi, R. F.; Carrilho, F. J.; Omata, M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 2001, 107, 449-455.
39. Perrillo, R.; Schiff, E.; Yoshida, E.; Statler, A.; Hirsch, K.; Wright, T.; Gutfreund, K.; Lamy, P.; Murray, A. Adefovir dipivoxil for the Treatment of Lamivudine-resistant Hepatitis B Mutants. Hepatology 2000, 32, 129-134.
40. Lee, B.; Luo, W.; Suzuki, S.; Robins, M. J.; Tyrrell, D. L. J. In vitro and in vivo Comparison of the Abilities of Purine and Pyrimidine 2′,3′-Dideoxynucleosides to Inhibit Duck Hepadnavirus. Antimicrob. Agents Chemother. 1989, 33, 336-339.
41. Tuttleman, J. S.; Pugh, J. C.; Summers, J. W. In vitro Experimental Infection of Primary Duck Hepatocyte Cultures with Duck Hepatitis B Virus. J. Virol. 1986, 58, 17-25.
42. Sells, M. A.; Chen, M. L.; Acs, M. L. Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected with Cloned Hepatitis B Virus DNA. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 1005-1009.
43. Robins, M. J.; Hatfield, P. W. Nucleic Acid Related Compounds. 37. Convenient and High-yield Synthesis of N-[(2-hydroxyethoxy)-methyl] Heterocycles as "Acyclic Nucleoside" Analogues. Can. J. Chem. 1982, 60, 547-553.